Using Cardiac Targeting Peptide to deliver miRNA for molecular reversal of heart failure
使用心脏靶向肽传递 miRNA 以分子逆转心力衰竭
基本信息
- 批准号:10481720
- 负责人:
- 金额:$ 28.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-13 至 2024-07-12
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAmino AcidsAngiotensin IIAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsAnimal ModelApoptosisArrhythmiaBiodistributionBiological AssayBiotinCRISPR/Cas technologyCardiacCardiac MyocytesCell membraneCell physiologyCellsCicatrixComplexCouplingDataDevelopmentDiseaseDoseEndothelial CellsEndotheliumEnvironmentEnzymesEpinephrineEventExposure toFamilyFibroblastsGene ActivationGene ExpressionGenesGoalsHealthHeartHeart HypertrophyHeart failureHumanIn VitroIndividualInflammationInjectionsIntravenousInvestigational DrugsKidneyKnock-outKnowledgeLabelLeftLegal patentLettersLinkLiverLogicLongevityLuciferasesMicroRNAsMolecularMorbidity - disease rateMorphologyMusMyocardiumMyofibroblastNucleic AcidsNucleotidesOrganPathologicPathway interactionsPatientsPatternPeptidesPersonsPharmaceutical PreparationsPharmacotherapyPhasePhase I Clinical TrialsPhenotypePhysiologicalPhysiologyPlant RootsPrevalenceProcessProtein IsoformsPublishingQuality of lifeRadioisotopesRecoveryRelaxationRoleSafetySignaling MoleculeSmall Business Technology Transfer ResearchStreptavidinStressTXN geneTechnologyTestingTherapeuticTissuesTranscriptional ActivationTreatment FailureWestern BlottingWild Type MouseWorkcalmodulin-dependent protein kinase IIcardiogenesiscell injuryclinical developmentcommercial applicationcommercializationcostcyanine dye 5disulfide bondimprovedin vivoin vivo evaluationin vivo imaging systeminduced pluripotent stem cellmortalitymouse modelnoveloverexpressionpre-clinicalside effectsymptom treatmentsynthetic peptidetargeted treatmenttechnological innovationtherapeutic miRNAtherapeutically effectivetime useuptakevector
项目摘要
PROJECT SUMMARY/ABSTRACT
Heart failure (HF) is a common disease with well-documented morbidity and mortality that affects
approximately 23 million people globally, including 6 million in the US. Current HF medications such as
Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs) treat the symptoms
of HF versus the root cause of the disease, which includes stressed myocardium that leads to hypertrophic
cardiomyocytes and endothelial inflammation.
CaMKIIδ is a signaling molecule that regulates cellular pathways involved in excitation‑contraction coupling
and relaxation events in the heart and transcriptional activation of genes related to cardiac hypertrophy,
inflammation, and arrhythmias. If left uncorrected, CaMKIIδ‑regulated changes culminate in a dysfunctional
myocardium and HF. The goal of this STTR Phase I project is to address this root cause of HF by delivering
miRNA to cardiomyocytes to down-regulate the over-expression and/or activation of CaMKIIδ because this
may allow damaged cardiomyocytes to regain normal function.
To achieve this goal, a specific miRNA will be selected that effectively inhibits the expression of CaMKIIδ in
vivo. This miRNA will then be conjugated to the proprietary cell penetrating peptide, Cardiac Targeting Peptide
(CTP), developed by Vivasc Therapeutics. This will create a CTP-miRNA conjugate that will deliver this
nucleotide specifically and directly to cardiomyocytes. CTP is a novel, synthetic peptide that has transduced (i)
normal mouse hearts in vivo (peak uptake at 15 minutes after injection), (ii) explanted human heart tissue, and
(iii) human derived iPSC beating cardiomyocytes. CTP has demonstrated robust transduction of normal
cardiomyocytes while sparing myofibroblasts, endothelial cells, and fibroblasts present in scar tissue. To date,
CTP conjugates have transduced cardiomyocytes carrying intact cargoes as diverse as radioisotopes, nucleic
acids, other peptides, and conjugates as large as the biotin-streptavidin complex. The team’s preliminary data
has shown that CTP is fully capable of carrying miRNA in a similar manner.
The hypothesis is that CTP-miRNA will deliver miRNA to cardiomyocytes that are over expressing CaMKIIδ,
thereby allowing damaged cardiomyocytes to regain normal function. The aims are: 1) deliver specific miRNAs
to the hearts of HF mouse models to demonstrate their efficacy in reversing HF physiology and 2) test the in
vivo biodistribution of CTP-miRNA using a dual-labeled CTP-miRNA.
Phase II plans include conducting studies of optimized CTP-miRNA in larger animal models of HF and IND-
enabling studies to support an Investigational New Drug (IND) submission for approval of a Phase 1 clinical
trial. Upon approval, this treatment could potentially be prescribed to HF patients with cardiac hypertrophy,
inflammation, and arrhythmias.
项目概要/摘要
心力衰竭(HF)是一种常见疾病,其发病率和死亡率均有充分记录,影响
全球约有 2300 万人,其中美国有 600 万人。目前的心力衰竭药物,例如
血管紧张素转换酶 (ACE) 抑制剂或血管紧张素受体阻滞剂 (ARB) 可治疗症状
心力衰竭的原因与疾病的根本原因,其中包括导致肥厚的心肌受压
心肌细胞和内皮炎症。
CaMKIIδ 是一种信号分子,调节参与兴奋-收缩耦合的细胞通路
心脏的松弛事件以及与心脏肥大相关的基因的转录激活,
炎症和心律失常。如果不加以纠正,CaMKIIδ 调节的变化最终会导致功能失调
心肌和心力衰竭。 STTR 第一阶段项目的目标是通过提供解决心衰的根本原因
miRNA 作用于心肌细胞以下调 CaMKIIδ 的过度表达和/或激活,因为这
可以使受损的心肌细胞恢复正常功能。
为了实现这一目标,将选择一种特定的 miRNA 来有效抑制 CaMKIIδ 的表达。
体内。然后,该 miRNA 将与专有的细胞穿透肽、心脏靶向肽缀合
(CTP),由 Vivasc Therapeutics 开发。这将创建一个 CTP-miRNA 缀合物,该缀合物将提供这种作用
核苷酸特异性地直接作用于心肌细胞。 CTP 是一种新型合成肽,已转导 (i)
体内正常小鼠心脏(注射后 15 分钟达到峰值吸收),(ii) 移植的人类心脏组织,以及
(iii) 人源 iPSC 跳动心肌细胞。 CTP 已表现出对正常细胞的强大转导作用
心肌细胞,同时保留疤痕组织中存在的肌成纤维细胞、内皮细胞和成纤维细胞。迄今为止,
CTP 缀合物已转导心肌细胞,其携带完整的货物,如放射性同位素、核酸
酸、其他肽和与生物素-链霉亲和素复合物一样大的缀合物。团队初步数据
已经表明CTP完全能够以类似的方式携带miRNA。
假设 CTP-miRNA 将 miRNA 传递至过度表达 CaMKIIδ 的心肌细胞,
从而使受损的心肌细胞恢复正常功能。目标是:1) 传递特定的 miRNA
注入心力衰竭小鼠模型的心脏,以证明其在逆转心力衰竭生理学方面的功效,并 2) 测试内部
使用双标记 CTP-miRNA 进行 CTP-miRNA 的体内生物分布。
II 期计划包括在 HF 和 IND 的大型动物模型中进行优化的 CTP-miRNA 研究
使研究能够支持研究性新药 (IND) 提交以批准 1 期临床
审判。一旦获得批准,这种治疗方法可能会用于患有心脏肥大的心力衰竭患者,
炎症和心律失常。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
G IAN GALLICANO其他文献
G IAN GALLICANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('G IAN GALLICANO', 18)}}的其他基金
Investigating deskmoplakin during vasculogenesis
研究血管生成过程中的 deskmoplakin
- 批准号:
6574003 - 财政年份:2002
- 资助金额:
$ 28.47万 - 项目类别:
Investigating deskmoplakin during vasculogenesis
研究血管生成过程中的 deskmoplakin
- 批准号:
6685992 - 财政年份:2002
- 资助金额:
$ 28.47万 - 项目类别:
Investigating deskmoplakin during vasculogenesis
研究血管生成过程中的 deskmoplakin
- 批准号:
6989775 - 财政年份:2002
- 资助金额:
$ 28.47万 - 项目类别:
Investigating deskmoplakin during vasculogenesis
研究血管生成过程中的 deskmoplakin
- 批准号:
6818777 - 财政年份:2002
- 资助金额:
$ 28.47万 - 项目类别:
FUNCTIONAL ANALYSIS: BAND 6 DURING MAMMALIAN DEVELOPMENT
功能分析:哺乳动物发育过程中的带 6
- 批准号:
2816005 - 财政年份:1998
- 资助金额:
$ 28.47万 - 项目类别:
FUNCTIONAL ANALYSIS: BAND 6 DURING MAMMALIAN DEVELOPMENT
功能分析:哺乳动物发育过程中的带 6
- 批准号:
2024970 - 财政年份:1997
- 资助金额:
$ 28.47万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 28.47万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




